Shares of ALX Oncology (NASDAQ: ALXO) had skyrocketed by 53% as of 11:10 a.m. ET on Tuesday. The huge gain came after the immuno-oncology company announced positive interim results from a phase 2 study evaluating evorpacept in combination with trastuzuma, Cyramza, and paclitaxel for treating HER2-positive gastric/gastroesophageal junction (GEJ) cancer. Just how positive were those interim results?
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles